9.03
Nuvectis Pharma Inc Azioni (NVCT) Dati Finanziari
Conto economico
Trimestrale
*Tutti i numeri sono espressi in milioni
| Data di fine periodo | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
| Durata del periodo | 3 mesi | 3 mesi | 3 mesi | 3 mesi | 3 mesi |
| Research and Development |
11.92%
5.086
|
5.774 | 3.613 | 3.68 | 4.496 |
| Operating Income/Loss |
2.27%
-7.617
|
-7.794 | -6.595 | -5.568 | -6.449 |
| Income/Loss From Continuing Operations Before Tax |
1.98%
-7.314
|
-7.462 | -6.334 | -5.332 | -6.248 |
| Income/Loss From Continuing Operations After Tax |
1.98%
-7.314
|
-7.462 | -6.334 | -5.332 | -6.248 |
|
|
1.98%
-7.314
|
-7.462 | -6.334 | -5.332 | -6.248 |
| Preferred Stock Dividends And Other Adjustments |
100.00%
-
|
2.429 | - | - | - |
| Attributable To Noncontrolling Interest |
-
|
- | - | - | - |
| Basic Average Shares |
97.97%
0.4615
|
22.72 | 21.37 | 19.94 | 0.2151 |
| Diluted Average Shares |
97.97%
0.4615
|
22.72 | 21.37 | 19.94 | 0.2151 |
| Basic Earnings Per Share |
29.55%
-0.31
|
-0.44 | -0.30 | -0.27 | -0.36 |
| Diluted Earnings Per Share |
29.55%
-0.31
|
-0.44 | -0.30 | -0.27 | -0.36 |
| Participating Securities, Distributed And Undistributed Earnings/Loss, Basic |
100.00%
-
|
2.429 | - | - | - |
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):